Company Overview and News
Thank you for joining the Cumberland Pharmaceuticals Third Quarter 2017 Financial Results and Corporate Update. Please be advised that this conference call is being recorded at the company’s request and will be archived on Cumberland’s website for one week from today’s date. (2-0)
* Cumberland Pharmaceuticals Inc files for mixed shelf of up to $100 million Source text: (bit.ly/2jazuqV) Further company coverage:
CPIX's bull case looks impressive on its face: huge cash balance, trailing twelve-month profits, four quarters of double-digit revenue growth, and a diversified drug portfolio, including four phase II candidates. (108-0)
In a sector where market-caps are cut in half daily and one good pick can make your portfolio for the year, Cumberland Pharmaceutical’s (CPIX) steady growth as a micro-cap biotech might raise some eyebrows. Cumberland has taken a very conservative approach to expansion in recent years - protecting cash reserves and not rushing strategic deals. This stock will certainly not make you rich overnight, but could return steady yields as a small part of your portfolio.
Thank you for joining the Cumberland Pharmaceuticals Company Update and Second Quarter 2017 Financial Report. Please be advised that this conference call is being recorded at the company's request and will be archived on Cumberland's website for one week from today's date.
When a person or group of persons acquires beneficial ownership of more than 5% of a company’s equity securities, they are required to file a Schedule 13D or 13G with the SEC.
Thank you for joining the Cumberland Pharmaceuticals First Quarter 2017 Financial Report and Company Update Conference Call. Please be advised that this call is being recorded at the company’s request and will be archived on Cumberland’s website for one week from today’s date.
New study data supports the use of Caldolor® in controlling pain and reducing opioid use in surgical patients
NEW YORK, NY / ACCESSWIRE / March 22, 2017 / Levi & Korsinsky announces it has commenced an investigation Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) concerning possible breaches of fiduciary duty. To obtain additional information, go to: http://zlk.9nl.com/cumberland-pharmaceuticals-cpix, or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
LONDON, March 14, 2017 /PRNewswire/ -- Scleroderma Diagnostics and Therapeutics Market: Overview Download the full report: https://www.reportbuyer.com/product/4463757/ Scleroderma, a very rare autoimmune disorder of the skin, is a term coined from the Greek words "sklerosis," which means hardness, and "derma," meaning skin. Thus, scleroderma literally translates to "hard skin." Scleroderma is a group of diseases that involves the abnormal growth of connective tissue, which supports the skin and internal organs.
Thank you for joining the Cumberland Pharmaceuticals conference call covering the Company's fourth quarter and FY '16 financial results. Please note that this call is recorded at Cumberland's request and will be archived on the Company's website for one week from today. I would now like to hand the call over to Erin Smith, who handles Corporate Relations for Cumberland. Erin, please go ahead.
NASHVILLE, Tenn., Feb. 7, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) today announced the publication of a multicenter clinical study demonstrating that Caldolor® (ibuprofen) Injection delivered significant fever reduction in hospitalized children. This study, which adds to the growing body of literature supporting Caldolor, evaluated the efficacy and safety of intravenous ibuprofen in pediatric patients, six months and older, with fever.
Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services company, today provides a trading update for the six months ended 31 December 2016.
2017-10-28 - Wilton
2017-10-25 - Wilton
2017-10-10 - Wilton
2017-10-09 - Wilton
2017-08-25 - Wilton